115 related articles for article (PubMed ID: 29621097)
1. Applying DDX3X Biomarker to Discriminate Atypical from Benign Meningiomas in Tissue Microarray.
Tsai WC; Hueng DY; Lin CR; Yang TCK; Nieh S; Gao HW
Appl Immunohistochem Mol Morphol; 2018 Apr; 26(4):263-267. PubMed ID: 29621097
[TBL] [Abstract][Full Text] [Related]
2. DDX3X Biomarker Correlates with Poor Survival in Human Gliomas.
Hueng DY; Tsai WC; Chiou HY; Feng SW; Lin C; Li YF; Huang LC; Lin MH
Int J Mol Sci; 2015 Jul; 16(7):15578-91. PubMed ID: 26184164
[TBL] [Abstract][Full Text] [Related]
3. ARID4B is a good biomarker to predict tumour behaviour and decide WHO grades in gliomas and meningiomas.
Tsai WC; Hueng DY; Nieh S; Gao HW
J Clin Pathol; 2017 Feb; 70(2):162-167. PubMed ID: 27451434
[TBL] [Abstract][Full Text] [Related]
4. Nrf2 Expressions Correlate with WHO Grades in Gliomas and Meningiomas.
Tsai WC; Hueng DY; Lin CR; Yang TC; Gao HW
Int J Mol Sci; 2016 May; 17(5):. PubMed ID: 27187376
[TBL] [Abstract][Full Text] [Related]
5. Benign versus atypical meningiomas: risk factors predicting recurrence.
Nowak A; Dziedzic T; Krych P; Czernicki T; Kunert P; Marchel A
Neurol Neurochir Pol; 2015; 49(1):1-10. PubMed ID: 25666766
[TBL] [Abstract][Full Text] [Related]
6. Osteopontin predicts the behaviour of atypical meningioma.
Lin CK; Tsai WC; Lin YC; Hueng DY
Histopathology; 2012 Jan; 60(2):320-5. PubMed ID: 22211290
[TBL] [Abstract][Full Text] [Related]
7. Necrosis is a consistent factor to recurrence of meningiomas: should it be a stand-alone grading criterion for grade II meningioma?
Góes P; Santos BFO; Suzuki FS; Salles D; Stávale JN; Cavalheiro S; de Paiva Neto MA
J Neurooncol; 2018 Apr; 137(2):331-336. PubMed ID: 29270884
[TBL] [Abstract][Full Text] [Related]
8. Atypical and anaplastic meningiomas: prognostic implications of clinicopathological features.
Yang SY; Park CK; Park SH; Kim DG; Chung YS; Jung HW
J Neurol Neurosurg Psychiatry; 2008 May; 79(5):574-80. PubMed ID: 17766430
[TBL] [Abstract][Full Text] [Related]
9. Immunohistochemical expression of SPARC is correlated with recurrence, survival and malignant potential in meningiomas.
Bozkurt SU; Ayan E; Bolukbasi F; Elmaci I; Pamir N; Sav A
APMIS; 2009 Sep; 117(9):651-9. PubMed ID: 19703125
[TBL] [Abstract][Full Text] [Related]
10. [Expression of HER2/neu in meningiomas: an immunohistochemistry and fluorescence in situ hybridization study].
Wang CL; Mei JH; Wang SS; Xu S; Xu LL; Xiong YF
Zhonghua Bing Li Xue Za Zhi; 2010 Mar; 39(3):156-60. PubMed ID: 20450760
[TBL] [Abstract][Full Text] [Related]
11. The application of flow cytometry for evaluating biological aggressiveness of intracranial meningiomas.
Lin YW; Tai SH; Huang YH; Chang CC; Juan WS; Chao LC; Wen MJ; Hung YC; Lee EJ
Cytometry B Clin Cytom; 2015; 88(5):312-9. PubMed ID: 25408130
[TBL] [Abstract][Full Text] [Related]
12. Clinicopathological variables, immunophenotype, chromosome 1p36 loss and tumour recurrence of 247 meningiomas grade I and II.
Ruiz J; Martínez A; Hernández S; Zimman H; Ferrer M; Fernández C; Sáez M; López-Asenjo JA; Sanz-Ortega J
Histol Histopathol; 2010 Mar; 25(3):341-9. PubMed ID: 20054806
[TBL] [Abstract][Full Text] [Related]
13. p-CREB expression in human meningiomas: correlation with angiogenesis and recurrence risk.
Barresi V; Branca G; Caffo M; Tuccari G
J Neurooncol; 2015 Mar; 122(1):87-95. PubMed ID: 25563814
[TBL] [Abstract][Full Text] [Related]
14. Tissue thioredoxin-interacting protein expression predicted recurrence in patients with meningiomas.
Cai Z; Zhang C; Zou Y; Lu C; Hu H; Qian J; Jiang L; Hu G
Int J Clin Oncol; 2017 Aug; 22(4):660-666. PubMed ID: 28243945
[TBL] [Abstract][Full Text] [Related]
15. Diagnosis and treatment of atypical and anaplastic meningiomas: a review.
Modha A; Gutin PH
Neurosurgery; 2005 Sep; 57(3):538-50; discussion 538-50. PubMed ID: 16145534
[TBL] [Abstract][Full Text] [Related]
16. Prognostic value of EGFR expression in de novo and progressed atypical and anaplastic meningiomas: an immunohistochemical and fluorescence in situ hybridization pilot study.
Caltabiano R; Barbagallo GM; Castaing M; Cassenti A; Senetta R; Cassoni P; Albanese V; Lanzafame S
J Neurosurg Sci; 2013 Jun; 57(2):139-51. PubMed ID: 23486338
[TBL] [Abstract][Full Text] [Related]
17. Clinicopathologic features of aggressive meningioma emphasizing the role of radiotherapy in treatment.
Engenhart-Cabillic R; Farhoud A; Sure U; Heinze S; Henzel M; Mennel HD; Bertalanffy H
Strahlenther Onkol; 2006 Nov; 182(11):641-6. PubMed ID: 17072521
[TBL] [Abstract][Full Text] [Related]
18. Prognostic value of ErbB2/HER2 in human meningiomas.
Arnli MB; Winther TL; Lydersen S; Torp SH
PLoS One; 2018; 13(10):e0205846. PubMed ID: 30335819
[TBL] [Abstract][Full Text] [Related]
19. Expression of ZIC family genes in meningiomas and other brain tumors.
Aruga J; Nozaki Y; Hatayama M; Odaka YS; Yokota N
BMC Cancer; 2010 Mar; 10():79. PubMed ID: 20199689
[TBL] [Abstract][Full Text] [Related]
20. Pediatric meningiomas an aggressive subset: a clinicopathological and immunohistochemical study.
Hui M; Uppin MS; Saradhi MV; Sahu BP; Purohit AK; Sundaram C
J Postgrad Med; 2015; 61(1):32-5. PubMed ID: 25511215
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
